Nausea and vomiting are chemotherapy adverse events that influence breast cancer patient's quality of life. Antiemetic regimen as premedication was given to prevent those adverse events and need to be evaluated.
Kristina, S. A. (S) +3 more
core
Perioperative Anesthesia Strategies for the Prevention of Postoperative Nausea and Vomiting Within Enhanced Recovery After Surgery Pathways: A Clinical Narrative Review. [PDF]
Dombrower R +3 more
europepmc +1 more source
Moving beyond promethazine: Advancing precision in antiemetic therapy. [PDF]
Ryan MF, Lagasse C.
europepmc +1 more source
Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovorin. [PDF]
Tokito Y +10 more
europepmc +1 more source
Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. [PDF]
Maeda K +13 more
europepmc +1 more source
Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study. [PDF]
Tada M +6 more
europepmc +1 more source
The effect of press-needle therapy on postoperative nausea and vomiting in patients undergoing bronchoscopy under general anesthesia in China: a quasi-experimental study. [PDF]
Li K +7 more
europepmc +1 more source
Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study. [PDF]
Ando Y +16 more
europepmc +1 more source
Optimising Non-operative Management of Inoperable Malignant Bowel Obstruction: A Clinical Review for Surgical Practice. [PDF]
Alkashty M, Kahka E, Hameed W, Eshra Y.
europepmc +1 more source
The impact of NK1 receptor antagonist selection on chemotherapy-related adverse events: a retrospective study of adverse events in paclitaxel or nab-paclitaxel and carboplatin combination therapy with fosnetupitant and aprepitant use. [PDF]
Yamaoka K +7 more
europepmc +1 more source

